


**Product Name** : Povorcitinib  
**Cat. No.** : PC-73438  
**CAS No.** : 1637677-22-5  
**Molecular Formula** : C<sub>23</sub>H<sub>22</sub>F<sub>5</sub>N<sub>7</sub>O  
**Molecular Weight** : 507.469  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



1. Alavi A, et al. *Br J Dermatol*. 2022 May;186(5):803-813.  
2. Fay B, He X, Margulis A et al. *Ann Rheum Dis*

## Biological Activity

Povorcitinib (INCB054707) is a potent, selective and oral **JAK1** inhibitor with IC<sub>50</sub> of 8.9 nM, 52-fold selective over JAK2 (IC<sub>50</sub>=463 nM).

Povorcitinib (INCB054707) reduces IFN signaling and ameliorates cutaneous lesions in systemic lupus erythematosus (SLE). Povorcitinib (INCB054707) dose-dependently reduced the incidence and severity of cutaneous lesion, abrogated lymphoid tissue and spleen enlargement in a preclinical model of cutaneous lupus erythematosus.

## References

2019; 78 (Suppl. 2):221-2.

